enGene Therapeutics Inc. (ENGNW) Operating cash flow 2022–2025
enGene Therapeutics Inc. (ENGNW) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$99.2MFY2025 · since FY2022: -$17.6M → -$99.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$99.2M | -105.5% |
| FY2024 | -$48.3M | -95.1% |
| FY2023 | -$24.7M | -40.6% |
| FY2022 | -$17.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ENGNW financial trends
ENGNW RevenueENGNW Net incomeENGNW Net marginENGNW Gross profitENGNW Gross marginENGNW Operating incomeENGNW Operating marginENGNW Free cash flowENGNW Capital expendituresENGNW Return on equityENGNW Stock buybacksENGNW Dividends paidENGNW Total assetsENGNW Total liabilitiesENGNW Shareholders’ equityENGNW overview →